Skip to main content

Praziquantel (Monograph)

Brand name: Biltricide
Drug class: Anthelmintics
VA class: AP200
Chemical name: 2-(Cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino(2,1-a)isoquinolin-4-one
CAS number: 55268-74-1

Introduction

Anthelmintic agent; pyrazinoisoquinoline derivative.2 3 4 5

Uses for Praziquantel

Schistosomiasis

Treatment of schistosomiasis (bilharziasis) caused by all Schistosoma species pathogenic to humans.1 14 15 16 17 18 19 20 21 24 25 26 27 28 29 30 32 33 34 35 38 40 41 42 55 56 87 88 89 128 133 134 140

Drug of choice for treatment of infections caused by S. haematobium, S. japonicum, S. mansoni, S. mekongi,3 4 6 9 11 14 15 16 29 32 33 34 38 55 87 88 89 128 133 134 and S. intercalatum.11

Used for treatment of individual patients3 9 12 14 16 17 21 140 and in mass-treatment and control programs.3 6 9 12 15 18 19 20 89

Effective against all stages of Schistosoma infection, including acute phase3 6 9 12 14 15 17 18 19 20 140 and chronic phase (which may be associated with hepatosplenic involvement).9 12 15 16 21 27 30 81

May be effective for treatment of severe schistosomiasis (e.g., neuroschistosomiasis).140 141 Initiate promptly to prevent substantial morbidity and long-term sequelae;140 141 may be initiated in cases of suspected neuroschistosomiasis pending results of confirmative tests.141

Cure rates generally lower in children6 38 and in patients with massive infections.6

Clonorchiasis

Treatment of clonorchiasis caused by Clonorchis sinensis (Chinese liver fluke).1 3 4 9 11 22 25 26 31 43 87 88 90 91 92 93 102 103 104 105 118 119 128 129 134 Drug of choice.87 88 128 134

Opisthorchiasis

Treatment of opisthorchiasis caused by Opisthorchis viverrini (Southeast Asian liver fluke).1 3 4 9 11 25 26 29 44 87 94 95 96 97 102 104 105 118 119 126 128 130 131 132 134 Drug of choice.87 88 128 130 134

Other Trematode (Fluke) Infections

Treatment of trematode (fluke) infections caused by Fasciolopsis buski† [off-label] (intestinal fluke),11 87 88 107 Heterophyes heterophyes† [off-label] (intestinal fluke),11 87 Metagonimus yokogawai† [off-label] (intestinal fluke),9 11 106 Metorchis conjunctus† [off-label] (North American liver fluke), Nanophyetus salmincola† [off-label] (formerly Troglotrema salmincola) (intestinal fluke),135 136 and Paragonimus westermani† (lung fluke).3 4 9 11 37 55 88 98 99 100 101 Drug of choice.55 87 88 134

Has been effective in a limited number of patients for treatment of infections caused by P. kellicotti† (American lung fluke),48 P. heterotrema† (lung fluke),111 and P. uterobilateralis† (African lung fluke).71

Has been used in a limited number of patients for treatment of infections caused by Fasciola hepatica† (sheep liver fluke),87 108 but treatment failures have been reported.88 110 134 Drug of choice is triclabendazole (not commercially available in the US); alternatives are bithionol (not commercially available in the US; may be available from the CDC) and nitazoxanide.134 146

Cestode (Tapeworm) Infections

Treatment of cestodiasis (tapeworm infections) caused by Diphyllobothrium latum† (fish tapeworm),2 4 46 47 134 Dipylidium caninum† (dog and cat tapeworm),46 134 Taenia saginata† (beef tapeworm),2 4 46 134 T. solium† (pork tapeworm),4 11 46 87 134 142 143 144 145 and Hymenolepis nana† (dwarf tapeworm).2 3 4 9 11 23 46 87 134

Drug of choice.55 87 134 Effective against the adult, juvenile, and larval stages of susceptible cestodes.4 46

Cysticercosis

Treatment of cysticercosis†, including neurocysticercosis†, caused by the larval form of T. solium (Cysticercus cellulosae).3 9 11 46 52 53 55 72 73 74 88 113 114 115 116 121 123 124 134

Praziquantel and albendazole are drugs of choice, but treatment of neurocysticercosis is controversial.55 134 147 148

Corticosteroids usually used concomitantly to reduce frequency and severity of adverse nervous system effects (CSF reaction syndrome).52 55 65 73 74 76 114 115 116 121 123 134 Anticonvulsant therapy also may be necessary.52 55 65 73 74 76 114 115 116 121 123 134

In some patients with neurocysticercosis†, risk of severe adverse effects may outweigh potential benefits.147 148

Do not use in patients with intraocular cysticercosis† because of risk of irreversible intraocular lesions secondary to killing of the cysts.1 88 85 117 Ocular and spinal cysts generally are not treated with anthelmintic drugs since irreparable damage may occur, even with concomitant corticosteroids.55 134

Hydatid Disease

Unlikely to be effective in the treatment of larval Echinococcus infections (hydatid cysts)†.4 60 61 Treatment of choice is surgical resection of the cysts; if surgery is contraindicated or cysts rupture spontaneously during surgery, mebendazole or albendazole is treatment of choice.83 134

Because praziquantel kills Echinococcus (e.g., protoscoleces), it may be useful for perioperative prophylaxis or when cyst contents are spilled during surgery.122 134

Praziquantel Dosage and Administration

Administration

Oral Administration

Administer orally with meals.1

Tablets may be halved or quartered to allow administration of individualized doses.1 Swallow the tablets, halves, and/or quarters with a sufficient amount of water during meals.1

Do not chew tablets.1 Retention of the tablets or tablet segments in the mouth may cause gagging or vomiting as a result of the drug's bitter taste.1

Dosage

Pediatric Patients

Schistosomiasis
Oral

Children ≥4 years of age: 20 mg/kg 3 times daily for 1 day; space doses 4–6 hours apart.1

Some clinicians recommend 20 mg/kg twice daily for 1 day for schistosomiasis caused by Schistosoma haematobium or S. mansoni.134 Doses of 40 mg/kg given as a single dose or in 2 equally divided doses have been effective in some patients with schistosomiasis caused by any species.3 6 9 12 14 15 16 17 19 20 128 133

Clonorchiasis
Oral

Children ≥4 years of age: 25 mg/kg 3 times daily for 1 day; 1 11 25 26 31 43 44 87 88 90 91 92 94 95 96 102 104 105 128 129 130 134 space doses 4–6 hours apart.1

Alternatively, 40–50 mg/kg given as a single dose has been effective in some patients,31 126 131 132 but may be associated with lower cure rates.31

Opisthorchiasis
Oral

Children ≥4 years of age: 25 mg/kg 3 times daily for 1 day;1 11 25 26 31 43 44 87 88 90 91 92 94 95 96 102 104 105 128 129 130 134 space doses 4–6 hours apart.1

Alternatively, 40–50 mg/kg given as a single dose has been effective in some patients,31 126 131 132 but may be associated with lower cure rates.31

Other Trematode (Fluke) Infections†
Fasciolopsis buski†, Heterophyes heterophyes†, or Metagonimus yokogawai† Infections
Oral

25 mg/kg 3 times daily for 1 day.11 87 88 134

Nanophyetus salmincola† Infections
Oral

20 mg/kg 3 times daily for 1 day.134 135 136

Paragonimus westermani† or P. uterobilateralis† Infections
Oral

25 mg/kg 3 times daily for 2 days.71 134

Fasciola hepatica† Infections
Oral

25 mg/kg 3 times daily for 5–8 days has been used,87 but treatment failures have occurred.88 110 134

Cestode (Tapeworm) Infections
Diphyllobothrium latum† (Fish Tapeworm), Dipylidium caninum† (Dog and Cat Tapeworm), Taenia saginata† (Beef Tapeworm), or T. solium† (Pork Tapeworm) Infections
Oral

5–10 mg/kg as a single dose.134

Hymenolepis nana† (Dwarf Tapeworm) Infections
Oral

25 mg/kg as a single dose.55 87 134 Eradication may be difficult; retreatment necessary if infection persists.55

Cysticercosis†
Oral

50–100 mg/kg given in 3 divided doses daily for 30 days.134

Adults

Schistosomiasis
Oral

20 mg/kg 3 times daily for 1 day; space doses 4–6 hours apart.1

Some clinicians recommend 20 mg/kg twice daily for 1 day for treatment of schistosomiasis caused by Schistosoma haematobium or S. mansoni.134 Doses of 40 mg/kg given as a single dose or in 2 equally divided doses have been effective in some patients with schistosomiasis caused by any species.3 6 9 12 14 15 16 17 19 20 128 133

Clonorchiasis
Oral

25 mg/kg 3 times daily for 1 day;1 11 25 26 31 43 44 87 88 90 91 92 94 95 96 102 104 105 128 129 130 134 space doses 4–6 hours apart.1

Alternatively, 40–50 mg/kg given as a single dose has been effective in some patients,31 126 131 132 but may be associated with lower cure rates.31

Opisthorchiasis
Oral

25 mg/kg 3 times daily for 1 day;1 11 25 26 31 43 44 87 88 90 91 92 94 95 96 102 104 105 128 129 130 134 space doses 4–6 hours apart.1

Alternatively, 40–50 mg/kg given as a single dose has been effective in some patients,31 126 131 132 but may be associated with lower cure rates.31

Other Trematode (Fluke) Infections†
Fasciolopsis buski†, Heterophyes heterophyes†, or Metagonimus yokogawai† Infections
Oral

25 mg/kg 3 times daily for 1 day. 11 87 88 134

Nanophyetus salmincola† Infections
Oral

20 mg/kg 3 times daily for 1 day.134 135 136

Paragonimus westermani† or P. uterobilateralis† Infections
Oral

25 mg/kg 3 times daily for 2 days.71 134

Fasciola hepatica† Infections
Oral

25 mg/kg 3 times daily for 5–8 days has been used, but treatment failures have occurred.88 110 134 .87

Cestode (Tapeworm) Infections
Diphyllobothrium latum† (Fish Tapeworm), Dipylidium caninum† (Dog and Cat Tapeworm), Taenia saginata† (Beef Tapeworm), or T. solium† (Pork Tapeworm) Infections
Oral

5–10 mg/kg as a single dose.134

Hymenolepis nana† (Dwarf Tapeworm) Infections
Oral

25 mg/kg as a single dose; re-treat if infection persists.55 87 134

Cysticercosis†
Oral

50–100 mg/kg given in 3 divided doses daily for 30 days.134

Neurocysticercosis†
Oral

50 mg/kg given in 3 equally divided doses daily for 14–21 days.52 53 72 74 88 113 115 116 121 Concomitant corticosteroids (e.g., dexamethasone 6–24 mg daily, prednisone 30–60 mg daily) often administered to reduce adverse nervous system effects.52 65 73 74 76 121

Consider repeating therapy in patients who show only partial resolution of cysts 3 months after a course or whose condition deteriorates.53 121 123

Special Populations

Hepatic Impairment

Use caution if usual dosage is used in patients with hepatosplenic schistosomiasis if they have moderate to severe liver impairment (Child-Pugh class B and C).1 (See Hepatic Impairment under Cautions.)

Renal Impairment

Dosage adjustments not necessary in patients with renal impairment.1 (See Pharmacokinetics.)

Geriatric Patients

No specific dosage recommendations at this time.1 (See Geriatric Use under Cautions.)

Detailed Praziquantel dosage information

Cautions for Praziquantel

Contraindications

Warnings/Precautions

Warnings

Interactions

Therapeutically effective praziquantel concentrations may not be achieved in patients receiving concomitant therapy with drugs that are strong inducers of CYP450 (e.g., rifampin).1 (See Specific Drugs and Food under Interactions.)

Sensitivity Reactions

Urticaria,1 14 15 16 42 93 100 128 maculopapular rash,102 103 111 128 pruritus,14 15 16 42 93 102 and a generalized hypersensitivity reaction, including polyserositis, have been reported.1

Mild eosinophilia has occurred in patients with schistosomiasis treated with praziquantel.19 40 Consider that eosinophilia can be associated with schistosomiasis38 50 and may be a consequence of a host-mediated immunologic response to antigen release during drug-induced killing of the worms.65 77 78 Similarly, urticaria may result from an immunologic response to antigen release from the worms.100

General Precautions

Precautions Related to Treatment of Neurocysticercosis

CSF reaction syndrome (headache, exacerbation of neurologic signs and symptoms such as seizures, increased CSF protein concentrations and anticysticercal IgG levels, arachnoiditis, meningism, hyperthermia, and intracranial hypertension)52 53 72 73 74 76 114 115 116 121 123 137 occurs in almost all53 74 121 patients during treatment for neurocysticercosis and may rarely be life-threatening.73 114 115 116 Use appropriate corticosteroid therapy to reduce the frequency and severity of adverse nervous system effects.72 73 74 76 114 115 116 121 123

Manufacturer recommends that patients with schistosomiasis who have cerebral cysticercosis be hospitalized during treatment.1

GI Effects

Abdominal pain or discomfort (with or without nausea) occurs frequently.1 3 4 14 15 16 17 38 40 41 42 89 90 91 93 94 96 98 100 102 104 107 108 112 126 130 Vomiting,1 14 15 16 19 38 41 42 93 100 103 107 112 epigastric pain,90 91 93 94 107 126 anorexia,1 14 90 91 92 93 94 98 126 urge to defecate,89 and diarrhea14 16 41 91 93 94 104 107 112 126 130 have been reported.

GI reactions, principally colicky, crampy abdominal pain, occasionally may be severe and occur suddenly within 1 hour after administration of the drug; may be accompanied by fever, sweating, and bloody stools.89

Hepatic Effects

Mild to moderate, transient increases in serum AST and/or ALT concentrations1 occur in about 3–27% of patients;16 104 no evidence of serious adverse hepatic effects, even in patients with schistosomal infection associated with severe hepatosplenic involvement.1 16 81 112

Patients with Cardiac Irregularities

Monitor patients with cardiac irregularities during praziquantel treatment.1

Specific Populations

Pregnancy

Category B.1

Lactation

Distributed into milk; temporarily discontinue nursing on the day of therapy and for 72 hours after administration of the last dose.1

Pediatric Use

Safety in children <4 years of age not established.1

Geriatric Use

Insufficient experience in those ≥65 years of age to determine whether they respond differently than younger adults.1 No evidence of substantial differences in safety and efficacy relative to younger adults, but increased sensitivity cannot be ruled out.1

Substantially eliminated by kidneys; decreased renal function associated with advanced age may increase risk of toxicity.1

Hepatic Impairment

Use caution in hepatosplenic patients with schistosomiasis who have moderate to severe liver impairment (Child-Pugh class B and C);1 hepatic metabolism may be decreased, resulting in considerably higher and more prolonged plasma concentrations of unchanged drug.1

Common Adverse Effects

Dizziness,1 3 15 16 19 41 42 89 90 91 92 93 94 98 102 103 104 107 111 112 126 128 headache,1 4 14 16 19 41 42 89 90 91 92 93 94 96 98 100 102 103 104 107 111 112 121 126 128 130 malaise,1 4 104 121 126 abdominal discomfort (with or without nausea).1 3 4 14 15 16 17 38 40 41 42 89 90 91 93 94 96 98 100 102 104 107 108 112 126 130

Drug Interactions

Metabolized by CYP isoenzymes (e.g., CYP3A).d

Drugs Affecting or Metabolized by Hepatic Microsomal Enzymes

Inhibitors of CYP isoenzymes: May increase plasma concentrations of praziquantel.1

Inducers of CYP isoenzymes: May reduce plasma concentrations of praziquantel.1

Specific Drugs and Food

Drug

Interaction

Comments

Anticonvulsants (carbamazepine, phenobarbital, phenytoin)

Decreased praziquantel concentrations1

Antifungals, azoles

Itraconazole or ketoconazole: Increased praziquantel concentrations1

Chloroquine

Decreased praziquantel concentrations1

Cimetidine

Increased praziquantel concentrations1 c

Dexamethasone

Decreased praziquantel concentrations1

Erythromycin

Increased praziquantel concentrations1

Grapefruit juice

Increased praziquantel concentrations1

Clinical importance unclear1

Rifampin

Decreased praziquantel concentrations and AUC1 d

Avoid concomitant use1 d
Praziquantel drug interactions (more detail)

Praziquantel Pharmacokinetics

Absorption

Bioavailability

About 80% of oral dose is rapidly absorbed from GI tract.1 9 36 Peak serum concentrations attained 1–3 hours after a dose.1

Extensive first-pass metabolism; only a small portion reaches systemic circulation as unchanged drug.4 9 10 36

Distribution

Extent

Distribution into human body tissues and fluids not fully characterized.65 80

In rats, concentrations of free (unbound) praziquantel in CSF were similar to those in serum.4 49 Drug concentration in CSF is 14–20% of the concurrent total (free plus protein-bound) plasma concentration.4

Distributed into milk in concentrations about 25% of maternal serum concentrations.1 36 112

Elimination

Metabolism

Rapidly and extensively metabolized, principally in the liver via hydroxylation to monohydroxylated and polyhydroxylated metabolites.4 36 Unknown if metabolites possess anthelmintic activity.65 80

Elimination Route

Approximately 70–80% of an oral dose excreted in urine within 24 hours, principally as metabolites;1 4 36 less than 0.1% of an oral dose excreted in urine unchanged.36

Half-life

Adults with normal renal and hepatic function: 0.8–1.5 hours.1 2 4 36 Half-life of metabolites is about 4–5 hours.4 36

Special Populations

Hepatic impairment: Pharmacokinetics in patients with Schistosoma mansoni infection and normal hepatic function or mild hepatic impairment (Child-Pugh class A) are similar, but half-life, peak serum concentrations, and AUC are increased in those with moderate to severe hepatic dysfunction (Child-Pugh class B and C).1 Half-life is about 3 hours in those with normal renal function, 4.7 hours in those with mild or moderate hepatic impairment (Child-Pugh class A or B), and 8.5 hours in those with severe hepatic impairment (Child-Pugh class C).1

Renal impairment: Excretion may be delayed; accumulation of unchanged drug not expected.1

Stability

Storage

Oral

Tablets

<30°C1 in tight containers.80

Actions and Spectrum

Advice to Patients

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

Praziquantel

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Tablets, film-coated

600 mg

Biltricide (with povidone; scored)

Bayer

AHFS DI Essentials™. © Copyright 2024, Selected Revisions January 1, 2008. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

† Off-label: Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

1. Bayer. Biltricide (praziquantel) tablets prescribing information. West Haven, CT; 2004 Aug.

2. Rollo IM. Drugs used in the chemotherapy of helminthiasis. In: Gilman AG, Goodman L, Gilman A, eds. Goodman and Gilman’s the pharmacological basis of therapeutics. 6th ed. New York: Macmillan Publishing Company; 1980:1024.

3. Anon. Praziquantel—a new antiparasitic drug. Med Lett Drugs Ther. 1982; 24:108-9. http://www.ncbi.nlm.nih.gov/pubmed/6755206?dopt=AbstractPlus

4. Pearson RD. Praziquantel: a major advance in anthelminthic therapy. Ann Intern Med. 1983; 99:195-8. http://www.ncbi.nlm.nih.gov/pubmed/6881777?dopt=AbstractPlus

5. Andrews P. A summary of the efficacy of praziquantel against schistosomes in animal experiments and notes on its mode of action. Arzneimittelforschung. 1981; 31:538-41. http://www.ncbi.nlm.nih.gov/pubmed/7016122?dopt=AbstractPlus

6. McMahon JE. Praziquantel: a new schistosomicide against Schistosoma haematobium. Br Med J. 1979; 2:1396-9. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1597073&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/519476?dopt=AbstractPlus

7. Mehlhorn H. Becker B, Andrews P et al. In vivo and in vitro experiments on the effects of praziquantel on Schistosoma mansoni. Arzneimittelforschung. 1981; 31:544-54. http://www.ncbi.nlm.nih.gov/pubmed/7195245?dopt=AbstractPlus

8. Webbe G, James C, Nelson GS et al. The effect of praziquantel on Schistosoma haematobium, S. japonicum and S. mansoni in primates. Arzneimittelforschung. 1981; 31:542-4. http://www.ncbi.nlm.nih.gov/pubmed/7195244?dopt=AbstractPlus

9. Owen JA. Praziquantel for the treatment of parasitic infections. Hosp Formul. 1983; 18:609-14.

10. Frohberg H. Toxicological profile of praziquantel, a new drug against cestode and schistosome infections, as compared to some other schistosomicides. Arzneimittelforschung. 1981; 31:555-65. http://www.ncbi.nlm.nih.gov/pubmed/7195246?dopt=AbstractPlus

11. Weniger BG. Praziquantel and refugee health. JAMA. 1984; 251:2391-2. http://www.ncbi.nlm.nih.gov/pubmed/6708289?dopt=AbstractPlus

12. Webbe G. Schistosomiasis: some advances. BMJ. 1981; 283:1104-6. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1507505&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/6794779?dopt=AbstractPlus

13. Anon. Praziquantel: a new hope for schistosomiasis. Lancet. 1980; 1:635-6. http://www.ncbi.nlm.nih.gov/pubmed/6102634?dopt=AbstractPlus

14. McMahon JE. Praziquantel: a new schistosomicide against Schistosoma mansoni. Arzneimittelforschung. 1981; 31:592-4. http://www.ncbi.nlm.nih.gov/pubmed/7195252?dopt=AbstractPlus

15. Smith DH, Highton RB. Preliminary observations on the treatment of schistosomiasis mansoni with praziquantel in Kenya. Arzneimittelforschung. 1981; 31:594-6. http://www.ncbi.nlm.nih.gov/pubmed/7195253?dopt=AbstractPlus

16. da Silva LC, Sette H Jr, Christo CH et al. Praziquantel in the treatment of the hepatosplenic form of schistosomiasis mansoni. Arzneimittelforschung. 1981; 31:601-3. http://www.ncbi.nlm.nih.gov/pubmed/7195256?dopt=AbstractPlus

17. Oyediran ABOO, Kofie BAK, Bammeke AO et al. Clinical experience with praziquantel in the treatment of Nigerian patients infected with S. haematobium. Arzneimittelforschung. 1981; 31:581-4. http://www.ncbi.nlm.nih.gov/pubmed/7016124?dopt=AbstractPlus

18. McMahon JE. Observations on praziquantel against Schistosoma haematobium. Arzneimittelforschung. 1981; 31:579-80. http://www.ncbi.nlm.nih.gov/pubmed/7195249?dopt=AbstractPlus

19. Davis A, Biles JE, Ulrich AM et al. Tolerance and efficacy of praziquantel in phase IIA and IIB therapeutic trials in Zambian patients. Arzneimittelforschung. 1981; 31:568-74. http://www.ncbi.nlm.nih.gov/pubmed/7195247?dopt=AbstractPlus

20. Pugh RNH. Single dose oral treatment in urinary schistosomiasis: a double blind trial. BMJ. 1983; 286:429-32. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1546776&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/6401550?dopt=AbstractPlus

21. Lorette G, Jaafar MR, Grojean MF et al. Schistosomiasis mekongi diagnosed by rectal biopsy. BMJ. 1983; 286:2012-3. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1548467&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/6409206?dopt=AbstractPlus

22. Qinan W, Jibai L, Yuehan L et al. Comparison of praziquantel, amoscanate and hexachloroparaxylol in clonorchiasis sinensis. Chin Med J. 1980; 93:849-56. http://www.ncbi.nlm.nih.gov/pubmed/6780274?dopt=AbstractPlus

23. Schenone H. Praziquantel in the treatment of Hymenolepis nana infections in children. Am J Trop Med Hyg. 1980; 29:320-1. http://www.ncbi.nlm.nih.gov/pubmed/7369452?dopt=AbstractPlus

24. Feldmeier H. Steiner A et al. Praziquantel compared to niridazole in schistosomiasis intercalatum therapy. Tropenmed Parasitol. 1981; 32:39-42. http://www.ncbi.nlm.nih.gov/pubmed/7233551?dopt=AbstractPlus

25. Horstmann RD, Feldheim W, Feldmeier H et al. High efficacy of praziquantel in the treatment of 22 patients with clonorchis/opisthorchis infections. Tropenmed Parasitol. 1981; 32:157-60. http://www.ncbi.nlm.nih.gov/pubmed/7345680?dopt=AbstractPlus

26. Loscher T, Nothdurft HD, Prufer L et al. Praziquantel in clonorchiasis and opisthorchiasis. Tropenmed Parasitol. 1981; 32:234-6. http://www.ncbi.nlm.nih.gov/pubmed/7345688?dopt=AbstractPlus

27. Davis A, Biles JE. Initial experiences with praziquantel in the treatment of human infection due to Schistosoma haematobium. Bull World Health Organ. 1979; 57:773-9. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=2395866&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/396053?dopt=AbstractPlus

28. Ishizaki T, Kamo E. Double-blind studies of tolerance to praziquantel in Japanese patients with Schistosoma japonicum infection. Bull World Health Organ. 1979; 57:787-91. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=2395874&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/396055?dopt=AbstractPlus

29. Katz N, Rocha RS. Preliminary trials with praziquantel in human infections due to Schistosoma mansoni. Bull World Health Organ. 1979; 57:781-5. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=2395863&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/396054?dopt=AbstractPlus

30. Santos AT, Blas BL, Nosenas JS et al. Preliminary clinical trials with praziquantel in Schistosoma japonicum infections in the Philippines. Bull World Health Organ. 1979; 57:793-9. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=2395875&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/396056?dopt=AbstractPlus

31. Rim HJ, Lyu KS, Lee JS et al. Clinical evaluation of the therapeutic efficacy of praziquantel (Embay 8440) against Clonorchis sinensis infection in man. Ann Trop Med Parasitol. 1981; 75:27-33. http://www.ncbi.nlm.nih.gov/pubmed/7023402?dopt=AbstractPlus

32. Katz N. Current results in the clinical therapy of schistosomiasis mansoni. Rev Inst Med Trop Sao Paulo. 1980; 22(Suppl. 4):8-17. http://www.ncbi.nlm.nih.gov/pubmed/7006041?dopt=AbstractPlus

33. Katz N, Rocha RS. Clinical trials with praziquantel in schistosomiasis mansoni. Rev Inst Med Trop Sao Paulo. 1981; 23:72-8. http://www.ncbi.nlm.nih.gov/pubmed/7025168?dopt=AbstractPlus

34. Schutte CHJ, Osman Y, Van Deventer JMG et al. Effectiveness of praziquantel against the South African strains of Schistosoma haematobium and S. mansoni. S Afr Med J. 1983; 64:7-10. http://www.ncbi.nlm.nih.gov/pubmed/6344270?dopt=AbstractPlus

35. Nash TE, Hofstetter M, Cheever AW et al. Treatment of Schistosoma mekongi with praziquantel: a double-blind study. Am J Trop Med Hyg. 1982; 31:977-82. http://www.ncbi.nlm.nih.gov/pubmed/6751116?dopt=AbstractPlus

36. Leopold G, Ungethum W, Groll E et al. Clinical pharmacology in normal volunteers of praziquantel, a new drug against schistosomes and cestodes: an example of a complex study covering both tolerance and pharmacokinetics. Eur J Clin Pharmacol. 1978; 14:281-91. http://www.ncbi.nlm.nih.gov/pubmed/729622?dopt=AbstractPlus

37. Spitalny KC, Senft AW, Meglio FD et al. Treatment of pulmonary paragonimiasis with a new broad-spectrum antihelmintic, praziquantel. J Pediatr. 1982; 101:144-46. http://www.ncbi.nlm.nih.gov/pubmed/7086613?dopt=AbstractPlus

38. Nash TE, Cheever AW, Ottesen EA et al. Schistosome infections in humans: perspectives and recent findings. Ann Intern Med. 1982; 97:740-54. http://www.ncbi.nlm.nih.gov/pubmed/6753683?dopt=AbstractPlus

40. Saif M. Observations on tolerance and efficacy of praziquantel in Egyptian patients infected simultaneously with S. haematobium and S. mansoni. Arzneimittelforschung. 1981; 31:604.

41. Omer AHS. Praziquantel in the treatment of mixed S. haematobium and S. mansoni infections. Arzneimittelforschung. 1981; 31:605-8. http://www.ncbi.nlm.nih.gov/pubmed/7195257?dopt=AbstractPlus

42. El-Alamy MA, Habib MA, McNeeley DF et al. Preliminary results of chemotherapy using praziquantel on a large scale in Qalyub bilharziasis project where simultaneous infection with S. mansoni and S. haematobium exists. Arzneimittelforschung. 1981; 31:612-15. http://www.ncbi.nlm.nih.gov/pubmed/7195259?dopt=AbstractPlus

43. Liu YH, Qiu ZD, Wang XG et al. Praziquantel in clonorchiasis sinensis: a further evaluation of 100 cases. Chin Med J (Beijing Engl Ed). 1982; 95:89-94.

44. Bunnag D. Studies on the chemotherapy of human opisthorchiasis in Thailand: I. Clinical trial of praziquantel. Southeast Asian J Trop Med Public Health. 1980; 11:528-31. http://www.ncbi.nlm.nih.gov/pubmed/7013095?dopt=AbstractPlus

45. Rim HJ. Chemotherapeutic effect of niclofan and praziquantel in the treatment of paragonimiasis. Korea Univ Med J. 1980; 17:113-28.

46. Groll E. Praziquantel for cestode infections in man. Acta Trop. 1980; 37:293-6. http://www.ncbi.nlm.nih.gov/pubmed/6106371?dopt=AbstractPlus

47. Bylund G, Bang B. Tests with a new compound (praziquantel) against Diphyllobothrium latum. J Helminthol. 1977; 51:115-9. http://www.ncbi.nlm.nih.gov/pubmed/886176?dopt=AbstractPlus

48. Pachucki CT, Levandowski RA, Brown VA et al. American paragonimiasis treated with praziquantel. N Engl J Med. 1984; 311:582-3. http://www.ncbi.nlm.nih.gov/pubmed/6749230?dopt=AbstractPlus

49. Krishnaswamy K, Teoh PC. Diseases of a tropical environment. In: Avery GS, ed. Drug treatment: principles and practice of clinical pharmacology and therapeutics. 2nd ed. New York: ADIS Press; 1980:1174-210.

50. Mahmoud AA. Schistosomiasis. N Engl J Med. 1977; 297:1329-31. http://www.ncbi.nlm.nih.gov/pubmed/917088?dopt=AbstractPlus

51. Warren KS. The relevance of schistosomiasis. N Engl J Med. 1980; 303:203-6. http://www.ncbi.nlm.nih.gov/pubmed/6991944?dopt=AbstractPlus

52. deGhetaldi LD, Norman RM. Cerebral cysticercosis treated biphasically with dexamethasone and praziquantel. Ann Intern Med. 1983; 99:179-81. http://www.ncbi.nlm.nih.gov/pubmed/6881772?dopt=AbstractPlus

53. Sotelo J, Escobedo F, Rodriguez-Carbajal J et al. Therapy of parenchymal brain cysticercosis with praziquantel. N Engl J Med. 1984; 310:1001-7. http://www.ncbi.nlm.nih.gov/pubmed/6708975?dopt=AbstractPlus

54. Shaw JR. The treatment of experimental schistosomiasis with a combination of oxamniquine and praziquantel. Trans R Soc Trop Med Hyg. 1983; 77:39-40. http://www.ncbi.nlm.nih.gov/pubmed/6679362?dopt=AbstractPlus

55. American Academy of Pediatrics. 2006 Red Book: Report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2006.

56. Centers for Disease Control and Prevention. Health information for international travel, 2003–2004. Atlanta, GA: US Department of Health and Human Services; 2003:141-3. Updates available from CDC website. http://www.cdc.gov/travel/yb/index.htm

57. Melhorn H, Kojima S, Rim HJ et al. Ultrastructural investigations on the effects of praziquantel on human trematodes from Asia: Clonorchis sinensis, Metagonimus yokogawai, Opisthorchis viverrini, Paragonimus westermani and Schistosoma japonicum. Arzneimittelforschung. 1983; 33:91-8. http://www.ncbi.nlm.nih.gov/pubmed/6338885?dopt=AbstractPlus

58. Kilpatrick ME, Farid Z, Bassily S et al. Treatment of Schistosoma mansoni with oxamniquine—five years’ experience. Am J Trop Med Hyg. 1981; 30:1219-22. http://www.ncbi.nlm.nih.gov/pubmed/7325280?dopt=AbstractPlus

59. Clarke VD. Oxamniquine (Vansil) in the treatment of Schistosoma mansoni infection in Rhodesia. Cent Afr J Med. 1977; 23(Suppl.):20-3. http://www.ncbi.nlm.nih.gov/pubmed/606374?dopt=AbstractPlus

60. Gemmell MA, Johnstone PD. The effect of praziquantel on Echinococcus granulosus, Taenia hydatigena and Taenia ovis infections in dogs. Res Vet Sci. 1977; 23:121-3. http://www.ncbi.nlm.nih.gov/pubmed/905644?dopt=AbstractPlus

61. Heath DD. The effect of mebendazole and praziquantel on the cysts of Echinococcus granulosus, Taenia hydatigena and T. ovis in sheep. NZ Vet J. 1978; 26:11-5.

62. Andrews P. The effect of praziquantel on Hymenolepis diminuta in vitro. Tropenmed Parasitol. 1979; 30:391-400. http://www.ncbi.nlm.nih.gov/pubmed/543005?dopt=AbstractPlus

63. Becker B, Melhorn H, Andrews P et al. Ultrastructural investigations on the effect of praziquantel on the tegument of five species of cestodes. Z Parasitenkd. 1981; 64:257-69. http://www.ncbi.nlm.nih.gov/pubmed/7222923?dopt=AbstractPlus

64. Bartsch H, Kuroki T, Malaveille C et al. Absence of mutagenicity of praziquantel, a new, effective, anti-schistosomal drug, in bacteria, yeasts, insects and mammalian cells. Mutat Res. 1978; 58:133-42. http://www.ncbi.nlm.nih.gov/pubmed/106268?dopt=AbstractPlus

65. Reviewers’ comments (personal observations); 1984 Oct.

66. Rollo IM. Drugs used in the chemotherapy of helminthiasis. In: Gilman AG, Goodman L, Gilman A, eds. Goodman and Gilman’s the pharmacological basis of therapeutics. 6th ed. New York: Macmillan Publishing Company; 1980: 1019-20.

67. Keusch GT. Anthelmintic therapy: the worm has turned. Drug Ther. 1982; 12:213-22.

68. Most H. Office management of common intestinal parasites. Drug Ther. 1973; 3:39-45.

69. Shaw MK. Schistosoma mansoni: dose-related tegumental surface changes after in vivo treatment with praziquantel. Z Parasitenkd. 1983; 69:643-53. http://www.ncbi.nlm.nih.gov/pubmed/6636985?dopt=AbstractPlus

70. Shaw MK. Schistosoma mansoni: the effects of a subcurative dose of praziquantel on the ultrastructure of worms in vivo. Z Parasitenkd. 1983; 69:73-9. http://www.ncbi.nlm.nih.gov/pubmed/6340360?dopt=AbstractPlus

71. Monson MH, Koenig JW. Successful treatment with praziquantel of six patients infected with the African lung fluke, Paragonimus uterobilateralis. Am J Trop Med Hyg. 1983; 32:371-5. http://www.ncbi.nlm.nih.gov/pubmed/6837846?dopt=AbstractPlus

72. Spina-Franca A, Nobrega JPS, Livramento JA et al. Administration of praziquantel in neurocysticercosis. Tropenmed Parasitol. 1982; 33:1-4. http://www.ncbi.nlm.nih.gov/pubmed/7101435?dopt=AbstractPlus

73. deGhetaldi LD, Norman RM. Praziquantel for cysticercosis of the brain parenchyma. N Engl J Med. 1984; 311:732-3.

74. Ciferri F. Praziquantel for cysticercosis of the brain parenchyma. N Engl J Med. 1984; 311:733.

75. Goldberg MA. Praziquantel for cysticercosis of the brain parenchyma. N Engl J Med. 1984; 311:733-4.

76. Sotelo J, Escobedo F, Rodriguez-Carbajal J et al. Praziquantel for cysticercosis of the brain parenchyma. N Engl J Med. 1984; 311:734. http://www.ncbi.nlm.nih.gov/pubmed/6433197?dopt=AbstractPlus

77. Ackerman SJ, Gleich GJ, Weller PF et al. Eosinophilia and elevated serum levels of eosinophil major basic protein and charcot-leyden crystal protein (lysophospholipase) after treatment of patients with Bancroft’s filariasis. J Immunol. 1981; 127:1093-8. http://www.ncbi.nlm.nih.gov/pubmed/7021674?dopt=AbstractPlus

78. Ottesen EA. Eosinophilia following treatment of patients with schistosomiasis mansoni and Bancroft’s filariasis. J Infect Dis. 1979; 139:343-7. http://www.ncbi.nlm.nih.gov/pubmed/448186?dopt=AbstractPlus

79. Billings PC. Effects of praziquantel, a new antischistosomal drug, on the mutation and transformation of mammalian cells. Cancer Res. 1982; 42:2692-6. http://www.ncbi.nlm.nih.gov/pubmed/7083161?dopt=AbstractPlus

80. Patchen JJ (Miles Pharmaceuticals, West Haven, CT): Personal communication; 1984 Nov 1.

81. Coutinho A, Domingues ALC, Neves J et al. Treatment of hepatosplenic schistosomiasis mansoni with praziquantel. Arzneimittelforschung. 1983; 33:787-91. http://www.ncbi.nlm.nih.gov/pubmed/6683560?dopt=AbstractPlus

82. Ni Y, Shao B, Zhan C et al. Mutagenic and teratogenic effects of anti-schistosomal praziquantel. Clin Med J. 1982; 95:494-8.

83. Keystone JS. Mebendazole. Ann Intern Med. 1979; 91:582-6. http://www.ncbi.nlm.nih.gov/pubmed/484964?dopt=AbstractPlus

85. Santos R, Chavarria M. Failure of medical treatment in two cases of intraocular cysticercosis. Am J Ophthalmol. 1984; 97:249-50. http://www.ncbi.nlm.nih.gov/pubmed/6607676?dopt=AbstractPlus

86. Frohberg H. Results of toxicological studies on praziquantel. Arzneimittelforschung. 1984; 34:1137-44. http://www.ncbi.nlm.nih.gov/pubmed/6542381?dopt=AbstractPlus

87. Turner JA. Drug therapy of gastrointestinal parasitic infections. The ACG Committee of FDA-Related Matters. Am J Gastroenterol. 1986; 81:1125-37. http://www.ncbi.nlm.nih.gov/pubmed/3538852?dopt=AbstractPlus

88. Katz M. Anthelmintics: current concepts in the treatment of helminthic infections. Drugs. 1986; 32:358-71. http://www.ncbi.nlm.nih.gov/pubmed/3780473?dopt=AbstractPlus

89. Santos AT, Blas BL, Portillo G et al. Phase III clinical trials with praziquantel in S. japonicum infections in the Phillipines. Arzneimittelforschung. 1984; 34:1221-3. http://www.ncbi.nlm.nih.gov/pubmed/6391506?dopt=AbstractPlus

90. Soh CT. Clonorchis sinensis: experimental and clinical studies with praziquantel in Korea. Arzneimittelforschung. 1984; 34:1156-9. http://www.ncbi.nlm.nih.gov/pubmed/6391503?dopt=AbstractPlus

91. Chen CY. Clonorchis sinensis: epidemiology in Taiwan and clinical experience with praziquantel. Arzneimittelforschung. 1984; 34:1160-2. http://www.ncbi.nlm.nih.gov/pubmed/6391504?dopt=AbstractPlus

92. Qi-Hong K, Yun-Tian Z, Shu-Zhoug L et al. Clonorchiasis: treatment with praziquantel in 50 cases. Arzneimittelforschung. 1984; 34:1162-3. http://www.ncbi.nlm.nih.gov/pubmed/6542382?dopt=AbstractPlus

93. Lee SH. Large scale treatment of Clonorchis sinensis infections with praziquantel under field conditions. Arzneimittelforschung. 1984; 34:1227-30. http://www.ncbi.nlm.nih.gov/pubmed/6542401?dopt=AbstractPlus

94. Bunnag D, Pungpark S, Harinasuta T et al. Opisthorchis viverrini: clinical experience with praziquantel in Hospital for Tropical Diseases. Arzneimittelforschung. 1984; 34:1173-4. http://www.ncbi.nlm.nih.gov/pubmed/6542386?dopt=AbstractPlus

95. Dhiensiri T, Eua-Ananta Y, Bunnag D et al. Roentgenographically controlled healing of gallbladder lesions in opisthorchiasis after praziquantel treatment. Arzneimittelforschung. 1984; 34:1175-7. http://www.ncbi.nlm.nih.gov/pubmed/6542387?dopt=AbstractPlus

96. Ambroise-Thomas P, Goullier A, Peyron F. Therapeutic results in opisthorchiasis with praziquantel in a reinfection-free environment in France. Arzneimittelforschung. 1984; 34:1177-9. http://www.ncbi.nlm.nih.gov/pubmed/6542388?dopt=AbstractPlus

97. Sornmani S, Schelp FP, Vivatanasesth P et al. A pilot project for controlling O. viverrini infection in Nong Wai, Northeast Thailand, by applying praziquantel and other measures. Arzneimittelforschung. 1984; 34:1231-4. http://www.ncbi.nlm.nih.gov/pubmed/6542402?dopt=AbstractPlus

98. Rim HJ. Paragonimiasis: experimental and clinical experience with praziquantel in Korea. Arzneimittelforschung. 1984; 34:1197-1203. http://www.ncbi.nlm.nih.gov/pubmed/6542393?dopt=AbstractPlus

99. Wei-Ji C, Lian-Yin H, Hui-Lan Z et al. Paragonimiasis: treatment with praziquantel in 40 human cases and in 1 cat. Arzneimittelforschung. 1984; 34:1203-4. http://www.ncbi.nlm.nih.gov/pubmed/6542394?dopt=AbstractPlus

100. Johnson RJ, Jong EC, Dunning SB et al. Paragonimiasis: diagnosis and the use of praziquantel in treatment. Rev Infect Dis. 1985; 7:200-6. http://www.ncbi.nlm.nih.gov/pubmed/4001715?dopt=AbstractPlus

101. Brown RW, Clarke RJ, Denham I et al. Pulmonary paragonimiasis in an immigrant from Laos. Med J Aust. 1983; 2:668-9. http://www.ncbi.nlm.nih.gov/pubmed/6669133?dopt=AbstractPlus

102. Jong EC, Wasserheit JN, Johnson RJ et al. Praziquantel for the treatment of Clonorchis/Opisthorchis infections: report of a double-blind, placebo-controlled trial. J Infect Dis. 1985; 152:637-40. http://www.ncbi.nlm.nih.gov/pubmed/3897401?dopt=AbstractPlus

103. Yangco BG, De Lerma C, Lyman GH et al. Clinical study evaluating efficacy of praziquantel in clonorchiasis. Antimicrob Agents Chemother. 1987; 31:135-8. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=174677&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/3551827?dopt=AbstractPlus

104. O’Keefe P, Edgett H. Efficacy and safety or praziquantel in the treatment of Clonorchis sinensisOpisthorchis viverrini: results of a double-blind, placebo-controlled trial in Southeast Asian refugees. Curr Ther Res. 1986; 40:411-7.

105. Hsu CCS. Clonorchiasis and praziquantel. Arch Intern Med. 1985; 145:1002-3. http://www.ncbi.nlm.nih.gov/pubmed/4004423?dopt=AbstractPlus

106. Cho SY, Kang SY. Metagonimiasis in Korea. Arzneimittelforschung. 1984; 34:1211-3. http://www.ncbi.nlm.nih.gov/pubmed/6542397?dopt=AbstractPlus

107. Harinasuta T, Bunnag D. Efficacy of praziquantel on fasciolopsiasis. Arzneimittelforschung. 1984; 34:1214-5. http://www.ncbi.nlm.nih.gov/pubmed/6542398?dopt=AbstractPlus

108. Schiappacasse RH, Mohammadi D. Successful treatment of severe infection with Fasciola hepatica with praziquantel. J Infect Dis. 1985; 152:1339-40. http://www.ncbi.nlm.nih.gov/pubmed/4067333?dopt=AbstractPlus

109. Becker B, Mehlhorn H, Andrews P et al. Light and electron microscopic studies on the effect of praziquantel on Schistosoma mansoni, Dicrocoelium dendriticum, and Fasciola hepatica (Trematoda) in vitro. Z Parasitenkd. 1980; 63:113-28. http://www.ncbi.nlm.nih.gov/pubmed/7456640?dopt=AbstractPlus

110. Farid Z, Trabolsi B, Boctor F et al. Unsuccessful use of praziquantel to treat acute fascioliasis. J Infect Dis. 1986; 154:920-1. http://www.ncbi.nlm.nih.gov/pubmed/2877032?dopt=AbstractPlus

111. Vanijanonta S, Bunnag D. Paragonimus heterotremus and other Paragonimus spp. in Thailand: pathogenesis, clinic and treatment. Arzneimittelforschung. 1984; 34:1186-8. http://www.ncbi.nlm.nih.gov/pubmed/6542391?dopt=AbstractPlus

112. Wegner DHG. The profile of the trematodicidal compound praziquantel. Arzneimittelforschung. 1984; 34:1132-6. http://www.ncbi.nlm.nih.gov/pubmed/6391500?dopt=AbstractPlus

113. Levin JA. Praziquantel in the treatment of cysticercosis. JAMA. 1986; 256:349. http://www.ncbi.nlm.nih.gov/pubmed/3723720?dopt=AbstractPlus

114. Richards F Jr. Praziquantel in the treatment of cysticercosis. JAMA. 1986; 256:349-50. http://www.ncbi.nlm.nih.gov/pubmed/3723720?dopt=AbstractPlus

115. Nash TE. Recent advances in the diagnosis and treatment of cerebral cysticercosis. N Engl J Med. 1984; 311:1492-6. http://www.ncbi.nlm.nih.gov/pubmed/6390196?dopt=AbstractPlus

116. Norman RM. Cerebral cysticercosis: treatment with praziquantel. Pediatrics. 1986; 78:291-4. http://www.ncbi.nlm.nih.gov/pubmed/3737306?dopt=AbstractPlus

117. Kestelyn P. Effect of praziquantel on intraocular cysticercosis: a case report. Br J Ophthalmol. 1985; 69:788-90. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1040740&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/4052366?dopt=AbstractPlus

118. Lin AC. Praziquantel and clonorchiasis. Antimicrob Agents Chemother. 1987; 31:1291. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=174924&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/3631948?dopt=AbstractPlus

119. Price DL. Praziquantel and clonorchiasis. Antimicrob Agents Chemother. 1987; 31:1291. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=174924&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/3631948?dopt=AbstractPlus

121. Earnest MP, Reller LB, Filley CM et al. Neurocysticercosis in the United States: 35 cases and a review. Rev Infect Dis. 1987; 9:961-79. http://www.ncbi.nlm.nih.gov/pubmed/3317739?dopt=AbstractPlus

122. Morris DL, Taylor DH, Daniels D et al. Determination of the minimum time of praziquantel therapy required for the in vitro treatment of protoscoleces of Echinococcus granulosus. J Helminthol. 1988; 62:10-4. http://www.ncbi.nlm.nih.gov/pubmed/3372974?dopt=AbstractPlus

123. Sotelo J, Torres B, Rubio-Donnadieu F et al. Praziquantel in the treatment of neurocysticercosis: long-term follow-up. Neurology. 1985; 35:752-5. http://www.ncbi.nlm.nih.gov/pubmed/3990975?dopt=AbstractPlus

124. Sotelo J, Escobedo F. Albendazole vs praziquantel for therapy for neurocysticercosis. A controlled trial. Arch Neurol. 1988; 45:532-4. http://www.ncbi.nlm.nih.gov/pubmed/3358706?dopt=AbstractPlus

126. Pungpak S, Bunnag D. Studies on the chemotherapy of human opisthorchiasis: effective dose of praziquantel in heavy infection. Southeast Asian J Trop Med Pub Hlth. 1985; 16:248-52.

127. Ruenwongsa P, Hutadilok N. Stimulation of Ca uptake in the human liver fluke Opisthorchis viverrini by praziquantel. Life Sci. 1983; 32:2529-34. http://www.ncbi.nlm.nih.gov/pubmed/6304438?dopt=AbstractPlus

128. King CH. Drugs five years later: praziquantel. Ann Intern Med. 1989; 110:290-6. http://www.ncbi.nlm.nih.gov/pubmed/2643915?dopt=AbstractPlus

129. O’Leary MJ, Berthiaume JT, Sakbun V. Treatment of Clonorchis sinensis in Hawaii’s Laotian population: experience with praziquantel. Hawaii Med J. 1985; 44:63-4. http://www.ncbi.nlm.nih.gov/pubmed/3980210?dopt=AbstractPlus

130. Supanvanich S, Supanvanich K. Field trial of praziquantel in human opisthorchiasis in Thailand. Southeast Asian J Trop Med Pub Hlth. 1981; 12:598-602.

131. Pungpak S, Bunnag D. Clinical and laboratory evaluation of praziquantel in opisthorchiasis. Southeast Asian J Trop Med Pub Hlth. 1983; 14:363-6.

132. Upatham ES, Viyanant V, Brockelman WY et al. Rate of reinfection by Opisthorchis viverrini in an endemic northeast Thai community after chemotherapy. Int J Parasit. 1988; 18:643-9.

133. Doehring E. Schistosomiasis in childhood. Eur J Pediatr. 1988; 147:2-9. http://www.ncbi.nlm.nih.gov/pubmed/3276525?dopt=AbstractPlus

134. Anon. Drugs for parasitic infections. Med Lett Drugs Ther. Aug 2004. From the Medical Letter website. http://www.medletter.com

135. Fritsche TR, Eastburn RL, Wiggins LH et al. Praziquantel for treatment of human Nanophyetus salmincola (Troglotrema salmincola) infection. J Infect Dis. 1989; 160:896-9. http://www.ncbi.nlm.nih.gov/pubmed/2809261?dopt=AbstractPlus

136. Harrell LW, Deardoff TL. Human nanophyetiasis: transmission by handling naturally infected coho salmon (Oncorhynchus kisutch). J Infect Dis. 1990; 161:146-8.

137. Bada JL, Trevino B. Convulsive seizures after treatment with praziquantel. BMJ. 1988; 296:646. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=2545278&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/3126947?dopt=AbstractPlus

138. Foreyt WJ. Evaluation of praziquantel against induced Nanophyetus salmincola infections in coyotes and dogs. Am J Vet Res. 1988; 49:563-5. http://www.ncbi.nlm.nih.gov/pubmed/3377318?dopt=AbstractPlus

139. Foreyt WJ. Preliminary evaluation of praziquantel against metacercariae of Nanophyetus salmincola in chinook salmon (Oncorhynchus tshawytscha). J Wildl Dis. 1988; 24:551-4. http://www.ncbi.nlm.nih.gov/pubmed/3411713?dopt=AbstractPlus

140. Centers for Disease Control and Prevention. Schistosomiasis in U.S. Peace Corps volunteers—Malawi, 1992. MMWR Morb Mortal Wkly Rep. 1993; 42:565-70. http://www.ncbi.nlm.nih.gov/pubmed/8332113?dopt=AbstractPlus

141. Blanchard TJ, Milne LM, Pollok R et al. Early chemotherapy of imported neuroschistosomiasis. Lancet. 1993; 341:959. http://www.ncbi.nlm.nih.gov/pubmed/8096291?dopt=AbstractPlus

142. St. Geme JW III, Maldonado YA, Enzmann D et al. Consensus: diagnosis and management of neurocysticercosis in children. Pediatr Infect Dis J. 1993; 12:455-61. http://www.ncbi.nlm.nih.gov/pubmed/8345976?dopt=AbstractPlus

143. Vazquez V. The course of seizures after treatment for cerebral cysticercosis. N Engl J Med. 1992; 327:696-701. http://www.ncbi.nlm.nih.gov/pubmed/1495522?dopt=AbstractPlus

144. Schantz PM, Moore AC, Mu˜noz JL et al. N Engl J Med. 1992; 327:692-5.

145. Despommier DD. Tapeworm infection—the long and the short of it. N Engl J Med. 1992; 327:727-8. http://www.ncbi.nlm.nih.gov/pubmed/1495527?dopt=AbstractPlus

146. Loutan L, Bouvier M, Rojanawisut B et al. Single treatment of invasive fascioliasis with triclabendazole. Lancet. 1989; 2:383. http://www.ncbi.nlm.nih.gov/pubmed/2569567?dopt=AbstractPlus

147. Garcia HH, Prtell EJ, Gilman RH et. A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis. N Engl J Med. 2004; 350:249-58. http://www.ncbi.nlm.nih.gov/pubmed/14724304?dopt=AbstractPlus

148. Sotelo J. Neurocysticercosis-is the elimination of parasites beneficial? N Engl J Med. 2004; 350:280-2. Editorial.

a. AHFS drug information 2007. McEvoy GK, ed. Praziquantel. Bethesda, MD: American Society of Health-System Pharmacists; 2007:54-7.

b. Robertson J, Shilkofski N, eds. The Harriet Lane handbook: a manual for pediatric house officers. 17th ed. Philadelphia, PA: Elsevier Mosby: 2005:937.

c. Jung H, Medina R, Castro N et al. Pharmacokinetic study of praziquantel administered alone and in combination with cimetidine in a single-day therapeutic regimen. Antimicrob Agents Chemother. 1997; 41:1256-9. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=163896&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/9174180?dopt=AbstractPlus

d. Ridtitid W, Wongnawa M, Mahatthanatrakul W et al. Rifampin markedly decreases plasma concentrations of praziquantel in healthy volunteers. Clin Pharmacol Ther. 2002; 72:505-13. http://www.ncbi.nlm.nih.gov/pubmed/12426514?dopt=AbstractPlus

Medical Disclaimer